“…Despite being effective in animal models of T2DM, as it is summarized in Table 2 , all acute [ 67 ], mid-term [ 68 , 69 ], and long-term [ 70 , 71 , 72 ] oral dosing of inorganic NO 3 − and NO 2 − , either as pharmacological forms (i.e., KNO 3 , NaNO 3 , and NaNO 2 ) or food-based supplementation (i.e., NO 3 − -rich beetroot juice or powder) have failed to show beneficial effects on glucose and insulin parameters, including fasting and post-prandial serum glucose and insulin concentrations, insulin resistance indices, and HbA1c levels in patients with T2DM. However, ergogenic [ 73 , 74 ] and beneficial cardiovascular effects of inorganic NO 3 − and NO 2 − , e.g., reducing peripheral and central systolic and diastolic blood pressures [ 75 ], have been highlighted in non-diabetic subjects by several clinical studies.…”